509
Participants
Start Date
November 30, 2014
Primary Completion Date
May 31, 2017
Study Completion Date
August 31, 2017
CYP2C19 genotyping
The study utilizes a genotyping device, SpartanRx™ (Spartan Bioscience, Ottawa, Canada) that provides identification of a patient's CYP2C19 \*2, \*3, and \*17 genotypes determined from genomic DNA from a buccal swab sample with 1 hour turnaround time
Hospital of the University of Pennsylvania, Philadelphia
Penn Presbyterian Medical Center, Philadelphia
University of Pennsylvania
OTHER